Diabetic retinopathy is a serious eye disease and ... hope to zero in on a new treatment pathway. They suspect the key to ...

“I think some of the new treatments will probably move the needle a little bit more in terms of treating this indication.” Ip MS. Update on the current treatment of diabetic retinopath ...

Proliferative diabetic retinopathy is clinically characterized ... resulting in sudden and severe vision loss. New pharmacological treatments that avoid deleterious impacts on visual function ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

People with type 2 diabetes who are taking empagliflozin are less likely to develop diabetic retinopathy compared to those not using the drug, new evidence has revealed. A recent study from the ...

(HealthDay News) — Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR ... up period of 8 months receiving treatment, the risk for incident ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

These fragile new vessels leak fluid that collects ... until significant damage occurs. What are the treatment options available for diabetic retinopathy? Early stages may only require ongoing ...

The risk for nonproliferative diabetic retinopathy progression was similar ... during a mean follow-up period of 8 months receiving treatment, the risk for incident NPDR did not differ across ...